Targeting hedgehog signaling in cancer: research and clinical developments

Area of Science:

• Molecular Biology
• Oncology
• Developmental Biology

Background:

• Hedgehog (Hh) signaling, first described in Drosophila, regulates key cellular processes including differentiation, proliferation, and stem cell maintenance.
• Hh signaling has been linked to various human cancers, including skin, lung, brain, and gastrointestinal malignancies.
• The first Hh signaling inhibitor, vismodegib, was approved in 2012 for basal cell carcinoma, indicating therapeutic potential.

Purpose of the Study:

• To review recent advances (last 3 years) in understanding Hh signaling activation in human cancer.
• To summarize developments in preclinical and clinical studies of Hh signaling inhibitors for cancer treatment.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of preclinical data on Hh signaling inhibitors.
• Evaluation of clinical trial outcomes for Hh signaling inhibitors.

Main Results:

• Significant progress has been made in elucidating the role of Hh signaling in diverse cancer types.
• Several Hh signaling inhibitors have shown promise in preclinical models and early-phase clinical trials.
• Understanding of Hh pathway activation mechanisms in cancer has expanded.

Conclusions:

• Hh signaling is a critical pathway in human carcinogenesis and a viable target for cancer therapy.
• Continued research into Hh signaling inhibitors may lead to new therapeutic strategies for various cancers.
• Further clinical investigation is warranted to optimize the use of Hh inhibitors in oncology.